Johnson & Johnson
NEW BRUNSWICK, NJ
$799m in 15 US stocks at the end of 30 June 2026. The top 10 are 98.4% of the money. It changed about 6.1% of the portfolio this quarter.
Value
$799m
Stocks
15
Top 10 share
98.4%
Turnover
6.1%
What changed this quarter
New
Bought for the first time this quarter.
- Cerebras SystemsCBRS1.5% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
- RallybioRLYB-100%
- Nano-X ImagingNNOX-100%
Holdings
- Legend BiotechLEGN
- Share
- 2.9%
- Value
- $24m
- Shares
- 814,586
Held
- Cerebras SystemsCBRS
- Share
- 1.5%
- Value
- $12m
- Shares
- 53,586
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Protagonist TherapeuticsPTGX | 37.6% | $300m | 2,449,183 | Held |
| NanobiotixNBTX | 26.5% | $212m | 5,623,816 | Held |
| MeiraGTx HoldingsMGTX | 11.2% | $90m | 6,641,064 | Held |
| Rapport TherapeuticsRAPP | 9.3% | $74m | 1,784,517 | Held |
| Contineum TherapeuticsCTNM | 4.1% | $32m | 1,979,173 | Held |
| Legend BiotechLEGN | 2.9% | $24m | 814,586 | Held |
| CVRxCVRX | 2.6% | $21m | 4,024,861 | Held |
| XencorXNCR | 1.5% | $12m | 748,062 | Held |
| Cerebras SystemsCBRS | 1.5% | $12m | 53,586 | New |
| Fate TherapeuticsFATE | 1.1% | $9m | 3,379,064 | Held |
| PROCEPT BioRoboticsPRCT | 1.0% | $8m | 357,939 | Held |
| Neumora TherapeuticsNMRA | 0.4% | $3m | 1,849,445 | Held |
| Vor BiopharmaVOR | 0.1% | $989,206 | 53,732 | Held |
| Standard BiotoolsLAB | <0.1% | $256,655 | 311,967 | Held |
| Adicet BioACET | <0.1% | $196,811 | 22,779 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 139.0% since 30 June 2025.
Where the money is
Health care95.6%
Technology1.5%
Other2.9%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.